Operation Warp Speed: implications for global vaccine security
- PMID: 33780663
- PMCID: PMC7997645
- DOI: 10.1016/S2214-109X(21)00140-6
Operation Warp Speed: implications for global vaccine security
Abstract
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
Copyright © 2021 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests JHK reports personal fees from SK Biosciences. MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E, a commercial vaccine manufacturer, for scale-up, production, testing, and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by the Scientific and Technological Research Council of Turkey since March, 2020. JPF and GK are members of the WHO Strategic Advisory Group of Experts in Immunization Working Group on COVID-19 vaccines. GK is independent director of Hilleman Laboratories and vice chair of the board for CEPI. SG is cofounder of Vaccitech and has a patent on ChAdOx1 nCoV-19 licensed to AstraZeneca. MH is founder and managing director of SaudiVax. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, and Celltrion, outside the submitted work. All other authors declare no competing interests.
Similar articles
-
A global survey in the developmental landscape of possible vaccination strategies for COVID-19.Clin Immunol. 2022 Apr;237:108958. doi: 10.1016/j.clim.2022.108958. Epub 2022 Feb 24. Clin Immunol. 2022. PMID: 35218966 Free PMC article. Review.
-
Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.Global Health. 2024 Mar 26;20(1):25. doi: 10.1186/s12992-024-01017-z. Global Health. 2024. PMID: 38532484 Free PMC article.
-
COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.Acta Med Indones. 2020 Oct;52(4):388-412. Acta Med Indones. 2020. PMID: 33377885 Review.
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383735 Free PMC article.
-
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34555004 Free PMC article.
Cited by
-
A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.Virology. 2022 Jan;566:56-59. doi: 10.1016/j.virol.2021.11.011. Epub 2021 Dec 1. Virology. 2022. PMID: 34864488 Free PMC article.
-
Choice preference and willingness to pay for COVID-19 vaccination in Namibia.Vaccine X. 2023 Aug;14:100324. doi: 10.1016/j.jvacx.2023.100324. Epub 2023 Jun 8. Vaccine X. 2023. PMID: 37333055 Free PMC article.
-
Factors, enablers and challenges for COVID-19 vaccine development.BMJ Glob Health. 2023 Jun;8(6):e011879. doi: 10.1136/bmjgh-2023-011879. BMJ Glob Health. 2023. PMID: 37277195 Free PMC article. Review.
-
Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.EClinicalMedicine. 2021 Sep;39:101053. doi: 10.1016/j.eclinm.2021.101053. Epub 2021 Aug 3. EClinicalMedicine. 2021. PMID: 34368661 Free PMC article. Review.
-
The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.Vaccines (Basel). 2023 Mar 17;11(3):690. doi: 10.3390/vaccines11030690. Vaccines (Basel). 2023. PMID: 36992275 Free PMC article. Review.
References
-
- Slaoui M, Hepburn M. Developing safe and effective COVID vaccines—Operation Warp Speed's strategy and approach. N Engl J Med. 2020;383:1701–1703. - PubMed
-
- Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27:205–211. - PubMed
-
- Baker S, Coons C. Inside Operation Warp Speed's $18 billion sprint for a vaccine. Oct 29, 2020. https://www.bloomberg.com/news/features/2020-10-29/inside-operation-warp...
-
- Rauhala E. As rich countries hoard potential coronavirus vaccine doses, rest of world could go without. Nov 2, 2020. https://www.washingtonpost.com/world/coronavirus-vaccine-doses-wealth-ga...
-
- Chinazzi M, Davis JT, Dean NE, et al. Estimating the effect of cooperative versus uncooperative strategies of COVID-19 vaccine allocation: a modeling study. Sept 14, 2020. https://www.networkscienceinstitute.org/publications/estimating-the-effe...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical